What technology area does this patent fall under?

Primary CPC classification A61K31/439. Mapped technology areas include Human Necessities.

When was this patent published?

Publication date Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.

What related patents are in patentsdb?

We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).

Glucosylceramide synthase inhibitors

US11008316B2 · US · B2

Patent metadata
Field	Value
Publication number	US-11008316-B2
Application number	US-201715490385-A
Country	US
Kind code	B2
Filing date	Apr 18, 2017
Priority date	Sep 11, 2012
Publication date	May 18, 2021
Grant date	May 18, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

Title
What the patent document calls the invention.
Abstract
A short plain-language summary of the technical disclosure.
Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
Key dates
Filing, priority, publication, and grant dates set the timeline.
First independent claim
The legal scope of protection — read this for what is actually claimed.
CPC / IPC classifications
Technology tags used to group this patent with similar filings.
Citations and related patents
Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to inhibitors of glucosylceramide synthase (GCS), such as Compound of Formula I, shown below, as defined herein, useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound of the formula or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 and at least one pharmaceutically acceptable carrier.

Assignees

Genzyme Corp

Inventors

Classifications

A61K31/496
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
A61K31/439Primary
the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46) · CPC title
A61K31/497
containing further heterocyclic rings · CPC title
A61K31/551
having two nitrogen atoms, e.g. dilazep · CPC title
C07D453/02Primary
containing not further condensed quinuclidine ring systems · CPC title

Patent family

Related publications grouped by family.

View patent family 49226563

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11008316B2 cover?: The invention relates to inhibitors of glucosylceramide synthase (GCS), such as Compound of Formula I, shown below, as defined herein, useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.
Who is the assignee on this patent?: Genzyme Corp
What technology area does this patent fall under?: Primary CPC classification A61K31/439. Mapped technology areas include Human Necessities.
When was this patent published?: Publication date Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?: We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).